@psybalazs@KingFranklinIV@N_Gukasyan @CybinInc Small Pharma's with/without SSRI study with DMT shows a possible enhancement of effect when patients stay on their SSRIs. Could explain the large effect seen here. Also placebo here returns to baseline, not worsening - it shows 1 day post dose
https://t.co/La0lZzN3BI
Three critiques of the current psychedelic renaissance:
1. Too much emphasis on clinical and therapeutic use
2. Legal policies donβt reflect the way majority of people use psychedelics
3. Too much done within structures of old systems; not enough building of new paradigms
Today we announce the positive top-line results of our Phase IIa study investigating the safety and efficacy of SPL026 with supportive therapy for the treatment of Major Depressive Disorder.
Full press release: https://t.co/xhMGIkFcst
#depression#mentalhealth#clinicaltrial
π£ Pleased to announce enrollment is complete in our SPL026 Phase IIa clinical trial in patients with major #depression. This is an important milestone in our development of DMT-assisted therapy & we eagerly await analysis of the study results. Full PR: https://t.co/MnCSKxCJSL
Our management team will host a conference call tomorrow at 8:30am EST/1:30pm GMT to discuss topline results from our Phase IIa clinical trial investigating SPL026 with supportive #therapy in patients with major #depression.
Conference call details in PR: https://t.co/vi9aeHSuH1
Pleased to share that Dr @ellenheather, our Director of R&D, will present the Phase I results of our SPL026 assisted-therapy #clinicaltrial at the annual @ECNPtweets Conference in Vienna on Sunday October 16.
Register to attend at: https://t.co/627JOqDk0k